Zongting Gu

Prof. Dr. Zongting Gu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Cancer Letters
Verified
Journal Article
Open access
ZGZongting Gu
Zongting Gu
YDYongxing Du
Yongxing Du
XZXueping Zhao
Xueping Zhao
CWChengfeng Wang
Chengfeng Wang
Pancreatic ductal adenocarcinoma (PDAC) is a solid malignant tumor with a very low operative rate and a poor patient prognosis. Therefore, gemcitabine (GEM)-based chemotherapy remains one of the most important treatment choices for PDAC. However, the efficacy of GEM monotherapy or GEM combination chemotherapy in improving the survival of patients with advanced PDAC is very limited, primarily due to GEM resistance. The mechanism of GEM resistance is complex and unclear. An extensive and dense fibrous matrix in the tumor microenvironment (TME) is an important feature of PDAC. Increasing evidence indicates that this fibrotic TME not only actively participates in the growth and spread of PDAC but also contributes to the induction of GEM resistance. Metabolic remodeling reduces GEM transport and synthesis in PDAC. This review focuses on the main cellular and molecular mechanisms underlying the involvement of the extracellular matrix (ECM), immune cells, and metabolic remodeling in the induction of GEM resistance; highlights the prospect of targeting the TME as an essential strategy to overcome GEM resistance; and provides new precise interventions for chemotherapy sensitization and improving the overall prognosis of patients with PDAC.

5 September 2023 in International Journal of Surgery
Verified
Journal Article
Open access
ZGZongting Gu
Zongting Gu
YDYongxing Du
Yongxing Du
PWPeng Wang
Peng Wang
XZXiaohao Zheng
Xiaohao Zheng
JHJin He
Jin He
JZJianwei Zhang
Jianwei Zhang
Background: Existing prediction models for clinically relevant postoperative pancreatic fistula (POPF) after pancreatoduodenectomy (PD) lack discriminatory power or are too complex. This study aimed to develop a simple nomogram that could accurately predict clinically relevant POPF after PD. Methods: A high-volume, multicenter cohort of patients who underwent PD from the American College of Surgeons-National Surgical Quality Improvement Program database in the United States during 2014–2017 was used as the model training cohort (n=3609), and patients who underwent PD from the Pancreatic Center of the National Cancer Center Hospital in China during 2014–2019 were used as the external validation cohort (n=1347). The study used lasso penalized regression to screen large-scale variables, then logistic regression was performed to screen the variables and build a model. Finally, a prediction nomogram for clinically relevant POPF was established based on the logistic model, and polynomial equations were extracted. The performance of the nomogram was evaluated by receiver operating characteristic curve, calibration curve, and decision curve analysis. Results: In the training and validation cohorts, there were 16.7% (601/3609) and 16.6% (224/1347) of patients who developed clinically relevant POPF, respectively. After screening using lasso and logistic regression, only six predictors were independently associated with clinically relevant POPF, including two preoperative indicators (weight and pancreatic duct size), one intraoperative indicator (pancreatic texture), and three postoperative indicators (deep surgical site infection, delayed gastric emptying, and pathology). The prediction of the new nomogram was accurate, with an area under the curve of 0.855 (95% CI: 0.702–0.853) in the external validation cohort, and the predictive performance was superior to three previously proposed POPF risk score models (all P<0.001, likelihood ratio test). Conclusions: A reliable lasso-logistic method was applied to establish a novel nomogram based on six readily available indicators, achieving a sustained, dynamic, and precise POPF prediction for PD patients. With a limited number of variables and easy clinical application, this new model will enable surgeons to proactively predict, identify, and manage pancreatic fistulas to obtain better outcomes from this daunting postoperative complication.

15 May 2022 in Advanced Science
Verified
Journal Article
Open access
YDYongxing Du
Yongxing Du
ZGZongting Gu
Zongting Gu
ZLZongze Li
Zongze Li
ZYZan Yuan
Zan Yuan
YZYue Zhao
Yue Zhao
CWChengfeng Wang
Chengfeng Wang
Structural variations (SVs) are the greatest source of variations in the genome and can lead to oncogenesis. However, the identification and interpretation of SVs in human cancer remain technologically challenging. Here, long‐read sequencing is first employed to depict the signatures of structural variations in carcinogenesis of human pancreatic ductal epithelium. Then widespread reprogramming of the 3D chromatin architecture is revealed by an in situ Hi‐C technique. Integrative analyses indicate that the distribution pattern of SVs among the 3D genome is highly cell‐type specific and the bulk remodeling effects of SVs in the chromatin organization partly depend on intercellular genomic heterogeneity. Meanwhile, contact domains tend to minimize these disrupting effects of SVs within local adjacent genomic regions to maintain overall stability. Notably, complex genomic rearrangements involving two key driver genes CDKN2A and SMAD4 are identified, and their influence on the expression of oncogenes MIR31HG, MYO5B, etc., are further elucidated from both a linear view and 3D perspective. Overall, this work provides a genome‐wide resource and highlights the impact, complexity, and dynamicity of the interplay between structural variations and high‐order chromatin organization, which expands the current understanding of the pathogenesis of SVs in human cancer.

16 July 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
ZZZhe Zhang
Zhe Zhang
XZXueping Zhao
Xueping Zhao
MSMinjie Shang
Minjie Shang
QXQiuran Xu
Qiuran Xu
XWXiaowei Wang
Xiaowei Wang
ZGZongting Gu
Zongting Gu
Objectives To develop and validate a machine learning model for precise risk stratification of postpancreaticoduodenectomy haemorrhage (PPH), enabling early identification of high-risk patients to guide clinical intervention. Design Retrospective international multicentre cohort study with model development and external validation. Setting Training data from the American College of Surgeons-National Surgical Quality Improvement Program database (USA, 2014–2017) and external validation data from the National Cancer Center (China, 2014–2019). Participants 3609 patients in the training cohort and 1347 in the validation cohort undergoing pancreaticoduodenectomy. Patients with missing data or non-relevant variables were excluded. Primary and secondary outcome measures Primary outcome: clinically relevant PPH (International Study Group of Pancreatic Surgery grades B/C). Secondary outcomes: model discrimination (area under the curve (AUC)), calibration (Hosmer-Lemeshow test), clinical utility (decision curve analysis) and risk stratification performance. Results The least absolute shrinkage and selection operator (Lasso)-gradient boosting machine model identified eight predictors: albumin, haematocrit (HCT), American Society of Anesthesiologists (ASA) class, operative time, vascular resection, sepsis, reoperation and pancreatic fistula. It achieved AUCs of 0.84 (95% CI 0.82 to 0.86) in training and 0.82 (95% CI 0.78 to 0.85) in validation, outperforming logistic regression and other machine learning models. Risk stratification into low-risk, medium-risk and high-risk groups showed strong discriminatory power (AUCs: 0.72–0.75). Decision curve analysis confirmed net clinical benefit, and SHapley Additive exPlanations values highlighted HCT and operative time as top contributors. The model was deployed as an interactive application for real-time risk assessment. Conclusions This novel machine learning model for PPH prediction integrates interpretable risk stratification and demonstrates robust performance across international cohorts. Its deployment as a clinical tool may facilitate proactive management of high-risk patients. Prospective validation is warranted prior to broad implementation.

10 December 2025 in International Journal of Surgery
Verified
Journal Article
Open access
YWYichen Wu
Yichen Wu
HXHaibo Xu
Haibo Xu
ZGZongting Gu
Zongting Gu
Background: Liver metastasis drives poor outcomes in pancreatic cancer, often precluding curative surgery. Traditional imaging misses occult lesions, risking futile resections. Artificial intelligence (AI) models integrating radiomics and clinical data promise enhanced preoperative detection, but evidence synthesis is lacking. Methods: This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy (PRISMA-DTA) guidelines. We searched PubMed and Web of Science (inception to May 2025) for studies using AI to predict liver metastasis in pancreatic ductal adenocarcinoma (PDAC). Diagnostic metrics were pooled via bivariate random-effects modeling. Results: Of 10 included studies, 6 (9,887 patients) enabled meta-analysis. Pooled AUC was 0.86 (95% CI: 0.83–0.89), sensitivity 0.78 (95% CI: 0.67–0.86), and specificity 0.80 (95% CI: 0.69–0.88). Larger sample sizes correlated with superior performance ( P = 0.0471). No publication bias was detected. Conclusions: AI models offer robust, noninvasive tools for predicting liver metastasis, enabling precise preoperative stratification to optimize surgical decisions and reduce unnecessary procedures. This review systematically summarizes available evidence on AI models predicting liver metastasis and provides practical implications for their clinical application in PDAC.

29 August 2025 in Surgery
Verified
Journal Article
Closed access
ZZZhe Zhang
Zhe Zhang
XZXueping Zhao
Xueping Zhao
HZHaopeng Zhu
Haopeng Zhu
LJLei Jin
Lei Jin
QXQiuran Xu
Qiuran Xu
ZGZongting Gu
Zongting Gu